Study of the Impact of VEGF Polymorphism on the Development of Renal

Status Recruiting

Clinical Trial Summary

Renal transplant patients have on average 3-5 times more risk of developing cancer than the general population. This rate can be increased up to 10 to 15 times in some type of cancer like kidney cancer. Among the identified risk factors, immunosuppressants and, in particular, calcineurin inhibitors (ciclosporin and tacrolimus) play a major role in increasing cancers apart from their depressant effects on the immune system.

Calcineurin inhibitors (CCN) are the basis of immunosuppressive therapy in renal transplantation. Several mechanisms have been implicated to explain their pro-oncogenic properties. One related to an increase in VEGF expression seems particularly interesting in the study of renal cell carcinoma in the transplanted patient. Indeed, the physiopathology of kidney cancer has clearly been associated with an increase in the production of VEGF. Furthermore, some polymorphisms of the gene encoding VEGF have already been associated with the survival of patients with renal carcinoma and the circulating level of VEGF in the general population. The search for an association between the polymorphisms of the VEGF gene and renal carcinoma in renal transplant patients could thus identify patients whose risk of renal cell carcinoma (cRCC) post-transplantation is increased. If the involvement of certain polymorphisms in the development of cRCC was confirmed in this population, their research before the introduction of the immunosuppressive treatment would make it possible to direct the choice of treatment towards molecules without pro-oncogenic property in the Patients such as mTOR protein inhibitors (sirolimus, everolimus). This research project is therefore in line with the desire to move towards a more "personalized" medicine that could be beneficial for the patient.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03114826
Study type	Observational
Source	Centre Hospitalier Universitaire, Amiens
Contact	Sandra BODEAU, Dr
Phone	+33322087034
Email	bodeau.sandra@chu-amiens.fr
Status	Recruiting
Phase	N/A
Start date	October 6, 2016
Completion date	October 5, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06026592` - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Active, not recruiting	`NCT02444429` - 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation	Phase 3
Completed	`NCT02238418` - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.	Phase 4
Completed	`NCT01729494` - Belatacept Early Steroid Withdrawal Trial	Phase 4
Terminated	`NCT01436305` - Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation	Phase 2
Terminated	`NCT01276834` - Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation	Phase 4
Completed	`NCT02843295` - Catalytic Antibodies to Predict Uninvasively Late Transplant Failure	N/A
Completed	`NCT00842699` - Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab	N/A
Completed	`NCT00525681` - Interaction Between Rimonabant and Cyclosporine and Tacrolimus	Phase 4
Completed	`NCT00189735` - A Study to Evaluate FK778 in Kidney Transplant Patients	Phase 2
Completed	`NCT00776750` - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients	Phase 4
Recruiting	`NCT04052867` - Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy	N/A
Completed	`NCT02587052` - A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
Completed	`NCT02020642` - Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)	N/A
Completed	`NCT01435291` - AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation	Phase 4
Recruiting	`NCT01001065` - Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis	N/A
Completed	`NCT00978965` - Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
Recruiting	`NCT00903188` - Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation	Phase 4
Completed	`NCT00419575` - Renal Transplantation With Immune Monitoring	N/A
Completed	`NCT00425308` - Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients — VE-CART

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms